Table 1.
Table of participant characteristics
| Characteristic | Overall (n = 143) | CU (n = 109) | MCI (n = 22) | Amnestic Dementia (n = 12) |
|---|---|---|---|---|
| Study, n (%) | ||||
| MCSA | 122 (85%) | 109 (100%) | 13 (59%) | 0 (0%) |
| ADRC | 21 (15%) | 0 (0%) | 9 (41%) | 12 (100%) |
| Age at tau PET, years | ||||
| Median (IQR) | 67 (60, 74) | 66 (60, 73) | 73 (66, 79) | 69 (62, 73) |
| Range | 32 to 94 | 32 to 94 | 55 to 94 | 55 to 83 |
| Sex, n (%) | ||||
| Female | 56 (39%) | 51 (47%) | 1 (5%) | 4 (33%) |
| Male | 87 (61%) | 58 (53%) | 21 (95%) | 8 (67%) |
| APOE ε4, n (%) | ||||
| Non-carrier | 96 (68%) | 78 (72%) | 16 (73%) | 2 (17%) |
| Carrier | 46 (32%) | 30 (28%) | 6 (27%) | 10 (83%) |
| Short Test of Mental Status, median (IQR) | 36 (34, 37) | 37 (35, 37) | 34 (31, 35) | 30 (24, 34) |
| Amyloid PET, SUVR | ||||
| Median (IQR) | 1.41 (1.33, 1.65) | 1.38 (1.32, 1.49) | 1.40 (1.33, 1.54) | 2.38 (2.31, 2.60) |
| SUVR ≥1.48 | 49 (34%) | 30 (28%) | 7 (32%) | 12 (100%) |
| Tau PET, SUVR* | ||||
| Median (IQR) | 1.16 (1.13, 1.24) | 1.15 (1.12, 1.20) | 1.21 (1.15, 1.30) | 1.89 (1.85, 2.13) |
| SUVR ≥1.29 | 24 (17%) | 6 (6%) | 6 (27%) | 12 (100%) |
| Entorhinal cortex tau PET, SUVR* | ||||
| Median (IQR) | 1.09 (1.04, 1.16) | 1.08 (1.04, 1.13) | 1.11 (1.05, 1.28) | 1.74 (1.59, 1.97) |
| SUVR ≥1.27 | 29 (20%) | 11 (10%) | 6 (27%) | 12 (100%) |
| CSF Aβ42, pg/mL** | ||||
| Median (IQR) | 1100 (801, 1454) | 1133 (858, 1519) | 1097 (711, 1503) | 524 (488, 589) |
| pg/ml≤1026 | 65 (45%) | 44 (40%) | 9 (41%) | 12 (100%) |
| CSF t-tau, pg/mL** | ||||
| Median (IQR) | 198 (161, 255) | 186 (149, 244) | 207 (176, 273) | 322 (269, 471) |
| pg/ml≥238 | 49 (34%) | 30 (28%) | 9 (41%) | 10 (83%) |
| CSF p-tau, pg/mL** | ||||
| Median (IQR) | 17 (14, 22) | 16 (13, 20) | 17 (15, 23) | 29 (25, 48) |
| pg/ml≥22 | 36 (25%) | 19 (17%) | 6 (27%) | 11 (92%) |
| Time from CSF to first tau PET scan, years | ||||
| Median (IQR) | −0.0 (−0.0, 2.5) | −0.0 (−0.0, 2.5) | −0.0 (−0.0, 1.2) | −0.0 (−0.0, 0.3) |
| Range | −0.3 to 2.9 | −0.3 to 2.9 | −0.1 to 2.9 | −0.2 to 1.2 |
| Tau PET scans, n (%) | ||||
| 2 | 106 (74%) | 87 (80%) | 13 (59%) | 6 (50%) |
| 3 | 33 (23%) | 22 (20%) | 5 (23%) | 6 (50%) |
| 4 | 4 (3%) | 0 (0%) | 4 (18%) | 0 (0%) |
| Time from first to last tau PET scan, years | ||||
| Median (IQR) | 2.6 (2.1, 3.7) | 2.6 (2.4, 3.7) | 1.9 (1.1, 2.9) | 1.7 (1.0, 2.2) |
| Range | 0.9 to 5.1 | 1.1 to 5.1 | 0.9 to 4.2 | 1.0 to 4.0 |
| Temporal meta-ROI tau PET rate, %/year, median (IQR)* | 0.5 (−0.1, 1.4) | 0.4 (−0.2, 1.1) | 0.6 (0.1, 1.0) | 5.4 (2.6, 7.9) |
| Entorhinal cortex tau PET rate, %/year, median (IQR)* | 0.8 (−0.2, 1.7) | 0.6 (−0.2, 1.5) | 1.3 (0.1, 2.7) | 3.3 (0.9, 4.3) |
*
The tau PET scans were processed with a longitudinal pipeline. SUVR values are summarized for the first tau PET scan.
**
The CSF visit is defined as the most recent visit with CSF on or within 3 years prior to the first tau PET visit.
Previously established biomarker cutpoints: CSF t-tau 238 pg/mL, CSF ptau181 22 pg/mL, CSF Aβ42 1026 pg/mL, amyloid PET 1.48 SUVR, temporal meta-ROI tau PET 1.29 SUVR, and entorhinal cortex tau PET 1.27 SUVR.